COVID-19: Epidemiyolojik bilgilerimiz ve hastalığın dünyadaki gidişi

Özgür Karcıoğlu

COVID-19: Epidemiyolojik bilgilerimiz ve hastalığın dünyadaki gidişi

Öz

Koronavirüs hastalığı (COVID-19) Mart 2020 itibarıyla dünyada 2.250.000’den fazla insanı etkilemiş ve 160.000’den fazla ölüme yol açmıştır. Üç ay içinde olgu sayısındaki istikrarlı ve hızlı artış COVID-19’un tüm dünyayı tehdit eden bir pandemiye dönüştüğünü anlatıyor. Halkın farkındalığının artırılarak sağlık kuruluşlarına bilinçli başvuruların yapılması, sağlık çalışanlarının da erken aşamadan başlayarak şüphelenmesi, tanı aşamalarında eksiklik yaşanmaması toplum sağlığı için önem taşımaktadır. Saptanan yüksek şüpheli veya tanılı olguların derhal izole edilmesi, gerektiğinde karantina uygulanması kilit önem taşır. Bu yazımızda pandeminin epidemiyolojik özellikleri, sosyodemografik faktörlerle ilişkisi özetlenmeye çalışılmıştır.

Anahtar Kelimeler

Koronavirus hastalığı,COVID-19,sosyodemografik faktörler,pandemi,epidemiyolojik özellikler

Kaynakça

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733.
2. Tang B, et al. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov). Infectious Disease Modelling 5 (2020) 248e255.
3. Imai, N., Cori, A., Dorigatti, I., Baguelin, M., Donnelly, C. A., Riley, S., et al. (2020). Report 3: Transmissibility of 2019-nCoV. Available at: https://www.imperial. ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-2019-nCoV-transmissibility.pdf.
4. Kucharski, A., Russell, T., Diamond, C., CMMID nCoV working group, Funk, S., & Eggo, R. (2020). Analysis of early transmission of 2019-nCoV and implications for outbreaks in new locations. Available at: https://cmmid.github.io/ncov/wuhan_early_dynamics/index.html.
5. Wu, J. T., Leung, K., & Leung, G. M. (2020). Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study. The Lancet. https://doi.org/10.1016/S0140-6736(20)30260-9.
6. Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. Version 2. F1000Res. 2020; 9: 72. Published online 2020 Feb 7. doi: 10.12688/f1000research.22211.2
7. Iuliano AD, Roguski KM, Chang HH, et al. Global Seasonal Influenza-associated Mortality Collaborator Network. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018 Mar 31;391(10127):1285-1300.
8. Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. [Article in Chinese] Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 2;48(0):E004.

9. Han L, Ran J, Mak YW, et al. Smoking and Influenza-associated Morbidity and Mortality: A Systematic Review and Meta-analysis. Epidemiology. 2019 May;30(3):405-417.
10. Lauer SA, Grantz KH, Bi Q, Jones FK, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020 Mar 10. doi: 10.7326/M20-0504. [Epub ahead of print]
11. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 2020 Mar 4. doi: 10.1002/ddr.21656. [Epub ahead of print] ¬
12. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr. 2007;44(2):179-87.
13. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Feb 19. doi: 10.5582/bst.2020.01047. [Epub ahead of print]
14. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J Roentgenol. 2020 Mar 3:1-6. doi: 10.2214/AJR.20.22976. [Epub ahead of print]
15. Rasmussen S, Smulian J, Lednicky J, et al. Coronavirus Disease 2019 (COVID-19) and Pregnancy: What obstetricians need to know. Am J Obst Gynecol 2020 doi: https://doi.org/10.1016/j.ajog.2020.02.017
16. Wang X, Zhou Z, Zhang J, et al. A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery. Clin Infect Dis 2020 doi: https://doi.org/10.1093/cid/ciaa200
17. https://www.who.int/emergencies/what-we-do/prevention-readiness/disease-commodity-packages/dcp-ncov.pdf?ua=1.
18. Li LQ, et al. 2019 novel coronavirus patients’clinical characteristics, discharge rate and fatality rate of meta-analysis. J Med Virol. 2020.
19. Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020.
20. Lim J, Jeon S, Shin HY, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci. 2020 Feb 17;35(6):e79.
21. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet 2020
22. Han, Q., Lin, Q., Jin, S., & You, L. Coronavirus 2019-nCoV: A brief perspective from the front line. J Infect. (2020). Feb 25. pii: S0163-4453(20)30087-6. doi:10.1016/j.jinf.2020.02.010
23. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020 Mar 9. pii: AAC.00399-20. doi: 10.1128/AAC.00399-20. [Epub ahead of print]
24. Ko WC, Rolain JM, Lee NY, et al. Arguments in favor of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020 Mar 5:105933. doi: 10.1016/j.ijantimicag.2020.105933.
25. Zhao et al. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study AJR 2020:215:1-6.
26. Zu ZY et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. Published Online: Feb 21 2020; https://doi.org/10.1148/radiol.2020200490
27. China Endorses Avigan / Favipiravir For COVID-19 Disease Treatment. URL: https://www.precisionvaccinations.com/avigan-favipiravir-t-705-broad-spectrum-inhibitor-viral-rna-polymerase?amp
28. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis Published Online First: 9 March 2020. doi:10.1093/cid/ciaa237
29. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020 Mar 5. doi: 10.1007/s00059-020-04909-z. [Epub ahead of print]
30. Qian GQ, Yang NB, Ding F, et al. Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series, QJM: An International Journal of Medicine, https://doi.org/10.1093/qjmed/hcaa089
31. IDM Coronavirus InfoHub: URL: https://docs.google.com/document/d/1UZ4eyAqaNnmO4kYKF-Z9-HWA0y0wyR30RRAT-_Wxi9c/preview
32. Wu, J.T., Leung, K., Bushman, M. et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med (2020).
33. Shim E, et al. Transmission potential and severity of COVID-19 in South Korea. Int J Infect Dis 2020, DOI: https://doi.org/10.1016/j.ijid.2020.03.031
34. Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. 2020 Feb 7. doi: 10.1001/jama.2020.1585. [Epub ahead of print]

Ayrıntılar

Birincil Dil

Türkçe

Konular

Acil Tıp

Bölüm

Derleme

Yazarlar

Özgür Karcıoğlu ^*
Türkiye

Yayımlanma Tarihi

23 Nisan 2020

Gönderilme Tarihi

18 Nisan 2020

Kabul Tarihi

22 Nisan 2020

Yayımlandığı Sayı

Yıl 2020 Cilt: 1 Sayı: 1

IZ

https://izlik.org/JA59HB92JL

Kaynak Göster

RIS / Bibtex

APA

Karcıoğlu, Ö. (2020). COVID-19: Epidemiyolojik bilgilerimiz ve hastalığın dünyadaki gidişi. Journal of ADEM, 1(1), 55-70. https://izlik.org/JA59HB92JL

AMA

1.Karcıoğlu Ö. COVID-19: Epidemiyolojik bilgilerimiz ve hastalığın dünyadaki gidişi. JADEM. 2020;1(1):55-70. https://izlik.org/JA59HB92JL

Chicago

Karcıoğlu, Özgür. 2020. “COVID-19: Epidemiyolojik bilgilerimiz ve hastalığın dünyadaki gidişi”. Journal of ADEM 1 (1): 55-70. https://izlik.org/JA59HB92JL.

EndNote

Karcıoğlu Ö (01 Nisan 2020) COVID-19: Epidemiyolojik bilgilerimiz ve hastalığın dünyadaki gidişi. Journal of ADEM 1 1 55–70.

IEEE

[1]Ö. Karcıoğlu, “COVID-19: Epidemiyolojik bilgilerimiz ve hastalığın dünyadaki gidişi”, JADEM, c. 1, sy 1, ss. 55–70, Nis. 2020, [çevrimiçi]. Erişim adresi: https://izlik.org/JA59HB92JL

ISNAD

Karcıoğlu, Özgür. “COVID-19: Epidemiyolojik bilgilerimiz ve hastalığın dünyadaki gidişi”. Journal of ADEM 1/1 (01 Nisan 2020): 55-70. https://izlik.org/JA59HB92JL.

JAMA

1.Karcıoğlu Ö. COVID-19: Epidemiyolojik bilgilerimiz ve hastalığın dünyadaki gidişi. JADEM. 2020;1:55–70.

MLA

Karcıoğlu, Özgür. “COVID-19: Epidemiyolojik bilgilerimiz ve hastalığın dünyadaki gidişi”. Journal of ADEM, c. 1, sy 1, Nisan 2020, ss. 55-70, https://izlik.org/JA59HB92JL.

Vancouver

1.Özgür Karcıoğlu. COVID-19: Epidemiyolojik bilgilerimiz ve hastalığın dünyadaki gidişi. JADEM [Internet]. 01 Nisan 2020;1(1):55-70. Erişim adresi: https://izlik.org/JA59HB92JL